Médecins du Monde challenges Gilead’s Sovaldi patent in EU
The high price of US biotech major Gilead Sciences’ (Nasdaq: GILD) blockbuster hepatitis C (HCV) drug Sovaldi (sofosbuvir) has come under attack again, this time from Doctors of the World - Médecins du Monde (MdM).
MdM reports that Gilead made more than $10 billion from Sovaldi last year. The charity has challenged Gilead’s monopoly by becoming the first medical non-governmental organization (NGO) to contest a drug patent with the European Patent Office. It hopes the legal challenge is just the first step to ensuring access to fairly priced generic treatments for hepatitis C and could inspire other organizations to take similar action.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze